Protection of Sacubitril/Valsartan against Pathological Cardiac Remodeling by Inhibiting the NLRP3 Inflammasome after Relief of Pressure Overload in Mice
Tóm tắt
The persistent existence of pathological cardiac remodeling, resulting from aortic stenosis, is related to poor clinical prognosis after successful transcatheter aortic valve replacement (TAVR). Sacubitril/valsartan (Sac/Val), comprising an angiotensin receptor blocker and a neprilysin inhibitor, has been demonstrated to have a beneficial effect against pathological cardiac remodeling, including cardiac fibrosis and inflammation in heart failure. The aim of this study was to determine whether Sac/Val exerts a cardioprotective effect after pressure unloading in mice. Male C57BL/6 J mice were subjected to debanding (DB) surgery after 8 weeks (wk) of aortic banding (AB). Cardiac function was assessed by echocardiography, which indicated a protective effect of Sac/Val after DB. After treatment with Sac/Val post DB, decreased heart weight and myocardial cell size were observed in mouse hearts. In addition, histological analysis, immunofluorescence, and western blot results showed that Sac/Val attenuated cardiac fibrosis and inflammation after DB. Finally, our data indicated that Sac/Val treatment could significantly suppress NF-κB signaling and NLRP3 inflammasome activation in mice after relief of pressure overload. Sac/Val exerted its beneficial effects to prevent maladaptive cardiac fibrosis and dysfunction in mice following pressure unloading, which was at least partly due to the inhibition of NLRP3 inflammasome activation.
Tài liệu tham khảo
Lindman BR, Dweck MR, Lancellotti P, et al. Management of asymptomatic severe aortic stenosis: evolving concepts in timing of valve replacement. JACC Cardiovasc Imaging. 2019. https://doi.org/10.1016/j.jcmg.2019.01.036
Prendergast BD, Redwood SR. Transcatheter aortic valve replacement. Circulation. 2019;139(24):2724–7.
Murdoch DJ, Webb JG, Ye J, et al. Transcatheter aortic-valve replacement - 10 years later. N Engl J Med. 2019;380(18):1773–4.
Miranda-Silva D, Goncalves-Rodrigues P, Almeida-Coelho J, et al. Characterization of biventricular alterations in myocardial (reverse) remodelling in aortic banding-induced chronic pressure overload. Sci Rep. 2019;9(1):2956.
Lefer DJ, Sharp TE 3rd. Angiotensin receptor-Neprilysin inhibitors emerge as potential treatment for acute myocardial infarction. J Am Coll Cardiol. 2018;72(19):2357–9.
Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, et al. Angiotensin-Neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019;380(6):539–48.
Burke RM, Lighthouse JK, Mickelsen DM, Small EM. Sacubitril/valsartan decreases cardiac fibrosis in left ventricle pressure overload by restoring PKG signaling in cardiac fibroblasts. Circ Heart Fail. 2019;12(4):e005565.
Jarcho J. PIONEERing the in-hospital initiation of Sacubitril-valsartan. N Engl J Med. 2019;380(6):590–1.
Wang Y, Li H, Li Y, et al. Coriolus versicolor alleviates diabetic cardiomyopathy by inhibiting cardiac fibrosis and NLRP3 inflammasome activation. Phytother Res. 2019;33(10):2737–2748.
Li X, Geng J, Zhao J, et al. Trimethylamine N-oxide exacerbates cardiac fibrosis via activating the NLRP3 Inflammasome. Front Physiol. 2019;10:866.
Gu J, Noe A, Chandra P, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010;50(4):401–14.
Xia Y, Chen Z, Chen A, et al. LCZ696 improves cardiac function via alleviating Drp1-mediated mitochondrial dysfunction in mice with doxorubicin-induced dilated cardiomyopathy. J Mol Cell Cardiol. 2017;108:138–48.
Bjornstad JL, Sjaastad I, Nygard S, et al. Collagen isoform shift during the early phase of reverse left ventricular remodelling after relief of pressure overload. Eur Heart J. 2011;32(2):236–45.
Szardien S, Nef HM, Voss S, et al. Regression of cardiac hypertrophy by granulocyte colony-stimulating factor-stimulated interleukin-1beta synthesis. Eur Heart J. 2012;33(5):595–605.
Byrne NJ, Levasseur J, Sung MM, et al. Normalization of cardiac substrate utilization and left ventricular hypertrophy precede functional recovery in heart failure regression. Cardiovasc Res. 2016;110(2):249–57.
Li X, Geng J, Chen Y, et al. Exposure to particulate matter induces cardiomyocytes apoptosis after myocardial infarction through NFkappaB activation. Biochem Biophys Res Commun. 2017;488(1):224–31.
Diwan A, Krenz M, Syed FM, et al. Inhibition of ischemic cardiomyocyte apoptosis through targeted ablation of Bnip3 restrains postinfarction remodeling in mice. J Clin Invest. 2007;117(10):2825–33.
Syed F, Diwan A, Hahn HS. Murine echocardiography: a practical approach for phenotyping genetically manipulated and surgically modeled mice. J Am Soc Echocardiogr. 2005;18(9):982–90.
Mahmood A, Pulakat L. Differential effects of beta-blockers, angiotensin II receptor blockers, and a novel AT2R agonist NP-6A4 on stress response of nutrient-starved cardiovascular cells. PLoS One. 2015;10(12):e0144824.
Zhao J, Li X, Hu J, et al. Mesenchymal stromal cell-derived exosomes attenuate myocardial ischaemia-reperfusion injury through miR-182-regulated macrophage polarization. Cardiovasc Res. 2019;115(7):1205–16.
Zhang X, Fu Y, Li H, et al. H3 relaxin inhibits the collagen synthesis via ROS- and P2X7R-mediated NLRP3 inflammasome activation in cardiac fibroblasts under high glucose. J Cell Mol Med. 2018;22(3):1816–25.
Musa TA, Treibel TA, Vassiliou VS, et al. Myocardial scar and mortality in severe aortic stenosis. Circulation. 2018;138(18):1935–47.
van der Meer P, Gaggin HK, Dec GW. ACC/AHA versus ESC guidelines on heart failure: JACC guideline comparison. J Am Coll Cardiol. 2019;73(21):2756–68.
Gao XM, Kiriazis H, Moore XL, et al. Regression of pressure overload-induced left ventricular hypertrophy in mice. Am J Physiol Heart Circ Physiol. 2005;288(6):H2702–7.
Ruppert M, Korkmaz-Icoz S, Loganathan S, et al. Incomplete structural reverse remodeling from late-stage left ventricular hypertrophy impedes the recovery of diastolic but not systolic dysfunction in rats. J Hypertens. 2019;37(6):1200–12.
Weinheimer CJ, Kovacs A, Evans S, Matkovich SJ, Barger PM, Mann DL. Load-dependent changes in left ventricular structure and function in a Pathophysiologically relevant murine model of reversible heart failure. Circ Heart Fail. 2018;11(5):e004351.
Balmforth C, Simpson J, Shen L, et al. Outcomes and effect of treatment according to etiology in HFrEF: an analysis of PARADIGM-HF. JACC Heart Fail. 2019;7(6):457–65.
Rodriguez-Gabella T, Catala P, Munoz-Garcia AJ, et al. Renin-angiotensin system inhibition following Transcatheter aortic valve replacement. J Am Coll Cardiol. 2019;74(5):631–41.
von Lueder TG, Wang BH, Kompa AR, et al. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. Circ Heart Fail. 2015;8(1):71–8.
Zile MR, O'Meara E, Claggett B, et al. Effects of Sacubitril/valsartan on biomarkers of extracellular matrix regulation in patients with HFrEF. J Am Coll Cardiol. 2019;73(7):795–806.
Ishii M, Kaikita K, Sato K, et al. Cardioprotective effects of LCZ696 (Sacubitril/valsartan) after experimental acute myocardial infarction. JACC Basic Transl Sci. 2017;2(6):655–68.
Xu F, Ji Q, Zhang J, Huang W, Cao Z, Li Y. AlCl3 inhibits LPS-induced NLRP3 inflammasome activation and IL-1beta production through suppressing NF-kappaB signaling pathway in murine peritoneal macrophages. Chemosphere. 2018;209:972–80.
Wang S, Lin Y, Yuan X, Li F, Guo L, Wu B. REV-ERBalpha integrates colon clock with experimental colitis through regulation of NF-kappaB/NLRP3 axis. Nat Commun. 2018;9(1):4246.
Yi H, Peng R, Zhang LY, et al. LincRNA-Gm4419 knockdown ameliorates NF-kappaB/NLRP3 inflammasome-mediated inflammation in diabetic nephropathy. Cell Death Dis. 2017;8(2):e2583.
Wu L, Mei L, Chong L, et al. Olmesartan ameliorates pressure overload-induced cardiac remodeling through inhibition of TAK1/p38 signaling in mice. Life Sci. 2016;145:121–6.